AR061973A1 - Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos - Google Patents

Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos

Info

Publication number
AR061973A1
AR061973A1 ARP070103095A ARP070103095A AR061973A1 AR 061973 A1 AR061973 A1 AR 061973A1 AR P070103095 A ARP070103095 A AR P070103095A AR P070103095 A ARP070103095 A AR P070103095A AR 061973 A1 AR061973 A1 AR 061973A1
Authority
AR
Argentina
Prior art keywords
alkyl
cooh
same
phenyl
hydroxyl
Prior art date
Application number
ARP070103095A
Other languages
English (en)
Inventor
Polenzani Lorenzo
Mangano Giorgina
Garrone Beatrice
Guglielmotti Angelo
Alessandra Alisi Maria
Cazzolla Nicola
Garofalo Barbara
Furlotti Guido
Maugeri Caterina
Omrato Rosella
Coletta Isabella
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of AR061973A1 publication Critical patent/AR061973A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Estos compuestos pueden utilizarse como reguladores de las prostaglandinas, para mejorar procesos inflamatorios, de vasodilatación y en terapia del dolor. Reivindicación 1: Compuesto de 2-arilindol sustituido en la posición 5, de fórmula (1), en la que X es un átomo de halógeno o un grupo alquilo C₁₋₃, trifluorometilo, nitro, amino, ciano, dialquil C₁₋₃amino, hidroxilo, alcoxilo C₁₋₃, fenilo o alquil C₁₋₃fenilo; Y y Z, que pueden ser iguales o diferentes, son un átomo de H o halógeno, o un grupo alquilo C₁₋₃, trifluorometilo, nitro, amino, dialquil C₁₋₃amino, hidroxilo, alcoxilo C₁₋₃, fenilo, COOH, alquil C₁₋₃-COOH, alquenil C₂₋₃-COOH, COOR, CONH₂, SO₂CH₃, SO₂NHCH₃ o NHSO₂CH₃; W es un átomo de O ó un grupo CH₂ o NH; R es un átomo de hidrógeno o un grupo alquilo C₁₋₆ o cicloalquilo C₃₋₇ sustituido opcionalmente con de 1 a 3 grupos hidroxilo; A es un grupo fenilo, naftilo o piridino sustituido opcionalmente con de 1 a 3 sustituyentes, que pueden ser iguales o diferentes, seleccionados de entre halógeno, alquilo C₁₋₆ sustituido opcionalmente con de 1 a 3 grupos hidroxilo, trifluorometilo, nitro, amino, dialquil C₁₋₃amino, hidroxilo, alcoxilo C₁₋₃, benciloxilo, COOH, COOR, SO₂CH₃, SO₂NHCH₃, NHSO₂CH₃, POR¹R², OPOR¹R², alquil C₁₋₆-COOH, alquenil C₂₋₆-COOH, fenilo y alquil C₁₋₃fenilo, en el que a su vez, R¹ y R² que pueden ser iguales o diferentes, son alquilo C₁₋₃; y sus sales de adición, estereoisómeros, enantiómeros, hidratos, solvatos y formas polimórficas fisiológicamente aceptables.
ARP070103095A 2006-07-14 2007-07-12 Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos AR061973A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT001368A ITMI20061368A1 (it) 2006-07-14 2006-07-14 Composto 2-arilindolico sostituito in posizione 5, composizione farmaceutica che lo comprende nonche' composti intermedi e procedimento per prepararlo

Publications (1)

Publication Number Publication Date
AR061973A1 true AR061973A1 (es) 2008-08-10

Family

ID=37895798

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103095A AR061973A1 (es) 2006-07-14 2007-07-12 Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos

Country Status (22)

Country Link
US (1) US8017644B2 (es)
EP (1) EP2049480B1 (es)
JP (1) JP5302191B2 (es)
KR (2) KR101440015B1 (es)
CN (1) CN101490000B (es)
AR (1) AR061973A1 (es)
AU (1) AU2007271865B2 (es)
BR (1) BRPI0712889A8 (es)
CA (1) CA2655750C (es)
DK (1) DK2049480T3 (es)
EA (1) EA015689B1 (es)
ES (1) ES2441594T3 (es)
GE (1) GEP20115166B (es)
HK (1) HK1124068A1 (es)
IL (1) IL196000A (es)
IT (1) ITMI20061368A1 (es)
MX (1) MX2009000492A (es)
PL (1) PL2049480T3 (es)
PT (1) PT2049480E (es)
SI (1) SI2049480T1 (es)
UA (1) UA96759C2 (es)
WO (1) WO2008006663A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2078711A1 (en) 2007-12-28 2009-07-15 AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A. (Aza)indole derivative substituted in position 5, pharmaceutical composition comprising it, intermediate compounds and preparation process therefor
AU2010232729A1 (en) 2009-03-31 2011-10-20 Arqule, Inc. Substituted indolo-pyridinone compounds
WO2011077313A1 (en) 2009-12-22 2011-06-30 Pfizer Inc. Piperidinecarboxamides as mpges - 1 inhibitors
CN103857657B (zh) 2011-08-18 2016-04-20 日本新药株式会社 杂环衍生物及医药
WO2013038308A1 (en) * 2011-09-15 2013-03-21 Glenmark Pharmaceuticals S.A. SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS AS mPGES-1 INHIBITORS
RU2681537C2 (ru) * 2014-04-14 2019-03-07 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Амидные производные и их фармацевтически приемлемые соли, способ их получения и медицинское применение
EP3178810A4 (en) * 2014-08-08 2018-07-04 Kasuma Partners Inc. Condensed heterocyclic compound
IL277071B1 (en) 2018-03-08 2024-03-01 Incyte Corp Aminopyrizine diol compounds as PI3K–y inhibitors
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
KR20210024983A (ko) * 2019-08-26 2021-03-08 국제약품 주식회사 인돌 카복사미드 유도체 및 그를 포함하는 약제학적 조성물
US11807644B2 (en) 2020-05-12 2023-11-07 Pmv Pharmaceuticals, Inc. Methods and compounds for restoring mutant p53 function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003270426A1 (en) * 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
WO2004069788A1 (ja) * 2003-02-07 2004-08-19 Ono Pharmaceutical Co., Ltd. カルボン酸化合物
ES2441206T3 (es) 2003-09-03 2014-02-03 Raqualia Pharma Inc. Compuestos de fenil o piridilamida como antagonistas de la prostaglandina E2
ITTO20040125A1 (it) * 2004-03-01 2004-06-01 Rotta Research Lab Nuove amidine eterocicliche inibitrici la produzione di ossido d'azoto (no) ad attivita' antinfiammatoria ed analgesica
GB0410121D0 (en) * 2004-05-06 2004-06-09 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
SI2049480T1 (sl) 2014-02-28
WO2008006663A1 (en) 2008-01-17
AU2007271865A1 (en) 2008-01-17
KR20140091569A (ko) 2014-07-21
GEP20115166B (en) 2011-02-25
KR20090054962A (ko) 2009-06-01
US20090186922A1 (en) 2009-07-23
KR101440015B1 (ko) 2014-09-12
DK2049480T3 (da) 2014-01-20
EA200970124A1 (ru) 2009-06-30
JP5302191B2 (ja) 2013-10-02
US8017644B2 (en) 2011-09-13
HK1124068A1 (en) 2009-08-07
ES2441594T3 (es) 2014-02-05
ITMI20061368A1 (it) 2008-01-15
EP2049480B1 (en) 2013-10-30
MX2009000492A (es) 2009-01-27
AU2007271865B2 (en) 2013-02-21
UA96759C2 (en) 2011-12-12
CN101490000B (zh) 2012-10-03
BRPI0712889A2 (pt) 2012-10-09
EA015689B1 (ru) 2011-10-31
IL196000A0 (en) 2009-09-01
CN101490000A (zh) 2009-07-22
EP2049480A1 (en) 2009-04-22
BRPI0712889A8 (pt) 2018-01-02
JP2009543766A (ja) 2009-12-10
CA2655750C (en) 2014-09-09
CA2655750A1 (en) 2008-01-17
PL2049480T3 (pl) 2014-03-31
PT2049480E (pt) 2013-12-16
IL196000A (en) 2013-10-31

Similar Documents

Publication Publication Date Title
AR061973A1 (es) Compuesto de 2-arilindol sustituido en la posicion 5, composicion farmaceutica que lo comprende, compuestos intermedios y procedimiento para la preparacion de los mismos
AR116993A2 (es) Compuestos heterociclos bicíclicos y sus usos en terapia
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR051754A1 (es) Metodos para preparar compuestos de indazol
CR20110013A (es) Derivados de Heteroarilo como Inhibidores de DGAT1
ECSP099388A (es) Derivados de azaadamatano y sus usos como ligandos de los receptores nicoticos de acetilcolina
CO6321248A2 (es) Derivados de triazol utiles para el tratamiento de enfermedades
PE20151981A1 (es) Pontenciador de inhibidores del homologo de zeste
UY29360A1 (es) Nuevos derivados de pirazol, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones.
EA201390163A1 (ru) Гетеробициклические производные в качетстве ингибиторов hcv
EA201000805A1 (ru) Бис-(сульфониламино)производные в терапии 066
AR086357A1 (es) Derivados de indazol sustituidos activos como inhibidores de quinasas
PE20121048A1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AR066155A1 (es) Compuestos de pirazol, simil tiroideo, composicion farmaceutica, proceso y uso en terapia
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
EA200602058A1 (ru) Производные адамантилпирролидин-2-она в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
EA200900213A1 (ru) Ингибиторы обратной транскриптазы вич (варианты), фармацевтическая композиция на их основе, способ ингибирования репликации ретровируса с их помощью и названные ингибиторы для изготовления лекарственного средства для ингибирования обратной транскриптазы вич и для лечения или профилактики инфекционного вич
CL2009000127A1 (es) Compuestos derivados de [indol, azaindol]-2-carboxamida sustituidos con un grupo silanilo; procedimiento de preparacion; compuestos intermediarios; composicion farmaceutica; y su uso en el tratamiento del dolor, inflamacion, trastornos metabolicos, entre otras enfermedades mediadas por la modulacion del receptor trpv1.
AR094346A1 (es) Derivados de azaindol como inhibidores de las proteína quinasas
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
AR105522A1 (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
AR069961A1 (es) Derivados de (aza)indol sustituidos en la posicion 5 utiles en el tratamiento de la inflamacion y el dolor, composiciones farmaceuticas que los comprenden, proceso de preparacion de los mismos y compuestos intermediarios.
AR104331A1 (es) Derivados de tetrazol

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed, e.g., due to non-payment of fee